Sutent® (sunitinib malate) – New indication
November 16, 2017 – The FDA announced the approval of Sutent (sunitinib malate) for the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy.
Download PDF
